Key facts
- This page summarizes David D. Meek's Form 4 filing for Mirati Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2023, 15:00.
David D. Meek - 20 Jan 2023 Form 4 Insider Report for Mirati Therapeutics, Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 20 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2023, 15:00:53 UTC
- Prior SEC filing
- 19 Jan 2023
- Next SEC filing
- 01 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Reena R. Desai,, Attorney-inFact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David D. Meek filed Form 4 for Mirati Therapeutics, Inc. on 24 Jan 2023.
Change
- Previous filing in this sequence was filed on 19 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +89,379
- Change %
- +145%
- Price
- $0.000000
- Shares after
- 151,171
- Date
- 20 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRTX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +151,233
- Change %
- Price
- $0.000000
- Shares after
- 151,233
- Date
- 20 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 151,233
- Exercise price
- $45.66
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
Footnote F2
25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.